<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BL-1 and BL-3</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Internal request**      | • Based on the noted reference, the panel consensus was to include single-dose intravesical gemcitabine within 24 hours of TURBT.  
• Based on the noted reference, the panel consensus was that immediate single-dose intravesical gemcitabine is supported by high-level evidence and this was added as a category 1 recommendation.  
|                           |                            | 14 | 0 | 3 | 11 |
| **BL-1 and BL-3**         |                            |                 |
| **Internal request**      | • Based on the noted reference, the panel consensus was that immediate single-dose intravesical mitomycin is supported by high-level evidence and the category was changed from a category 2A to a category 1 recommendation.  